DYDC2 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the DYDC2 gene. This loss-of-function model is generated in HAP1 cells and provides a genetically heterogeneous pool ideal for studying DYDC2-dependent phenotypes without the constraints of clonal selection.
The host cell line, HAP1, is a near-haploid cell line derived from a male chronic myeloid leukemia patient. Its haploid karyotype facilitates efficient gene disruption and simplifies genotype-phenotype analyses, making it a preferred model for functional genomic screens. As a hematopoietic progenitor cell model, HAP1 retains features relevant to blood cell biology and oncogenic transformation, enabling the study of gene function in a disease-relevant context.
DYDC2 encodes a protein containing a DPY30 domain, which mediates dimerization and incorporation into COMPASS/Set1-like methyltransferase complexes. Within these complexes, DYDC2 interacts with core components including ASH2L, RBBP5, WDR5, and MLL family members (KMT2A-D) to facilitate histone H3K4 trimethylation at target gene promoters. This activity activates transcription of key developmental regulators such as HOX genes and other loci marked by H3K4me3, linking DYDC2 to chromatin remodeling and transcriptional regulation pathways.
In HAP1 cells, disruption of DYDC2 is expected to impair the assembly or function of H3K4 methyltransferase complexes, leading to reduced H3K4me3 levels and altered expression of developmental genes. This model is particularly valuable for dissecting epigenetic mechanisms in cancer, where dysregulation of histone methylation contributes to aberrant gene expression programs. The haploid background ensures that even subtle epigenetic perturbations can be detected, enhancing the sensitivity of functional assays.
Researchers can employ this polyclonal knockout pool in a variety of applications, including functional genomics, epigenetic regulation studies, cancer gene function screening, and drug target validation. Representative assays include Western blotting for global H3K4me3 changes, RT-qPCR for quantifying target gene expression, ChIP-qPCR to assess locus-specific histone modifications, and RNA-seq for transcriptome-wide profiling. These cells provide a robust loss-of-function system for exploring DYDC2 biology. For additional technical information or ordering inquiries, please contact Ascent Research.
